CA2981055A1 - Spirocyclic compounds - Google Patents

Spirocyclic compounds Download PDF

Info

Publication number
CA2981055A1
CA2981055A1 CA2981055A CA2981055A CA2981055A1 CA 2981055 A1 CA2981055 A1 CA 2981055A1 CA 2981055 A CA2981055 A CA 2981055A CA 2981055 A CA2981055 A CA 2981055A CA 2981055 A1 CA2981055 A1 CA 2981055A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
alkyl
cancer
diazaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2981055A
Other languages
English (en)
French (fr)
Inventor
Peter Qinhua HUANG
Mehmet Kahraman
Deborah Helen Slee
Kevin Duane Bunker
Chad Daniel Hopkins
Joseph Robert Pinchman
Sunny Abraham
Rakesh Kumar Sit
Daniel Lee Severance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recurium IP Holdings LLC
Original Assignee
Kalyra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalyra Pharmaceuticals Inc filed Critical Kalyra Pharmaceuticals Inc
Publication of CA2981055A1 publication Critical patent/CA2981055A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2981055A 2015-04-03 2016-03-31 Spirocyclic compounds Abandoned CA2981055A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562142946P 2015-04-03 2015-04-03
US62/142,946 2015-04-03
PCT/US2016/025345 WO2016161160A1 (en) 2015-04-03 2016-03-31 Spirocyclic compounds

Publications (1)

Publication Number Publication Date
CA2981055A1 true CA2981055A1 (en) 2016-10-06

Family

ID=57007413

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2981055A Abandoned CA2981055A1 (en) 2015-04-03 2016-03-31 Spirocyclic compounds

Country Status (25)

Country Link
US (3) US10525036B2 (https=)
EP (1) EP3277690B1 (https=)
JP (1) JP6737533B2 (https=)
KR (1) KR20170132307A (https=)
CN (1) CN107849053B (https=)
AU (1) AU2016242940B2 (https=)
BR (1) BR112017021194A2 (https=)
CA (1) CA2981055A1 (https=)
CY (1) CY1123019T1 (https=)
DK (1) DK3277690T3 (https=)
ES (1) ES2788160T3 (https=)
HR (1) HRP20200805T1 (https=)
HU (1) HUE049481T2 (https=)
IL (1) IL254662B (https=)
LT (1) LT3277690T (https=)
MX (1) MX379622B (https=)
PL (1) PL3277690T3 (https=)
PT (1) PT3277690T (https=)
RS (1) RS60340B1 (https=)
RU (1) RU2745069C2 (https=)
SG (1) SG11201707911VA (https=)
SI (1) SI3277690T1 (https=)
SM (1) SMT202000279T1 (https=)
TW (1) TWI705067B (https=)
WO (1) WO2016161160A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10308609B2 (en) * 2014-09-17 2019-06-04 Zeno Royalties & Milestones, LLC Bicyclic compounds
MX379622B (es) 2015-04-03 2025-03-11 Recurium Ip Holdings Llc Compuestos espirociclicos
AU2017339890A1 (en) * 2016-10-05 2019-04-11 Recurium Ip Holdings, Llc Spirocyclic compounds
KR20190087622A (ko) 2016-12-08 2019-07-24 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 질환 치료를 위한 이중 류신 지퍼 (dlk) 키나아제의 바이시클로[1.1.1]펜탄 억제제
PE20211455A1 (es) * 2018-01-31 2021-08-05 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
CA3137152A1 (en) 2019-04-18 2020-10-22 The Johns Hopkins University Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
US11560366B2 (en) 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
AU2021362678A1 (en) 2020-10-13 2023-05-04 The Johns Hopkins University SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
WO2008063609A2 (en) 2006-11-17 2008-05-29 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
US8716483B2 (en) 2008-02-21 2014-05-06 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
JP2013506669A (ja) * 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Erk阻害剤である新規化合物
EP3296398A1 (en) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
CN103130775B (zh) 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US8987264B2 (en) 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
US9447026B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
MX379622B (es) 2015-04-03 2025-03-11 Recurium Ip Holdings Llc Compuestos espirociclicos
AU2017339890A1 (en) 2016-10-05 2019-04-11 Recurium Ip Holdings, Llc Spirocyclic compounds

Also Published As

Publication number Publication date
TW201710261A (zh) 2017-03-16
KR20170132307A (ko) 2017-12-01
EP3277690A1 (en) 2018-02-07
WO2016161160A1 (en) 2016-10-06
DK3277690T3 (da) 2020-05-04
AU2016242940B2 (en) 2020-11-05
US10525036B2 (en) 2020-01-07
EP3277690B1 (en) 2020-02-26
BR112017021194A2 (pt) 2019-01-08
RU2017133973A (ru) 2019-05-06
US10493060B2 (en) 2019-12-03
MX2017012553A (es) 2018-04-11
RU2745069C2 (ru) 2021-03-18
RS60340B1 (sr) 2020-07-31
SI3277690T1 (sl) 2020-07-31
HK1256671A1 (en) 2019-09-27
MX379622B (es) 2025-03-11
SG11201707911VA (en) 2017-10-30
JP2018511613A (ja) 2018-04-26
US20180207132A1 (en) 2018-07-26
CY1123019T1 (el) 2021-10-29
IL254662A0 (en) 2017-11-30
CN107849053A (zh) 2018-03-27
PT3277690T (pt) 2020-03-24
SMT202000279T1 (it) 2020-07-08
US20200268714A1 (en) 2020-08-27
US20190201380A1 (en) 2019-07-04
IL254662B (en) 2021-02-28
TWI705067B (zh) 2020-09-21
AU2016242940A1 (en) 2017-10-26
ES2788160T3 (es) 2020-10-20
JP6737533B2 (ja) 2020-08-12
CN107849053B (zh) 2020-10-30
HRP20200805T1 (hr) 2020-10-16
HUE049481T2 (hu) 2020-09-28
RU2017133973A3 (https=) 2019-07-17
LT3277690T (lt) 2020-06-10
PL3277690T3 (pl) 2020-08-24
EP3277690A4 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
JP6949952B2 (ja) スピロ環化合物
US10493060B2 (en) Spirocyclic compounds
KR102645995B1 (ko) Rsv 억제제로서의 병용 약학 제제
US12297190B2 (en) Modulators of STING (stimulator of interferon genes)
JP7112324B2 (ja) Rsv阻害剤としてのベンゾジアゼピン誘導体
RU2717238C2 (ru) Соединения 1-циано-пирролидинов в качестве ингибиторов USP30
EP3828179A1 (en) Cyanopyrrolidines as dub modulators
HK1256671B (en) Spirocyclic compounds
NZ751398B2 (en) Spirocyclic compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210319

FZDE Discontinued

Effective date: 20230926